Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.

结果本例患临床症状既无明显胸痛,也无腹痛与腹胀,行性加重的呼吸困难为表。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并肝硬化的慢性丙肝（CHC）患α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。

Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.

结果本例患者临床症状既无明,也无腹与腹胀,而以进行性加重的呼吸困难为表。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并肝硬化的慢性丙肝（CHC）患者接受α干扰素包括派罗时存在肝功能失代偿和死亡风险。

Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.

结果本例患者临床症状既无明显胸痛,也无腹痛与腹胀,而以进行性加重的呼吸困。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

硬化的慢性丙（CHC）患者接受α干扰素包括派罗欣治疗时存在功能失代偿和死亡风险。

Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.

结果本例患者临床症状既无明显胸,也无胀,而以进行性加重的呼吸困难为表。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并肝硬化的慢性丙肝（CHC）患者接受α干扰派罗欣治疗时存在肝功能失代偿和死亡风险。

Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.

结果本例患者临床无明显胸痛,也无腹痛与腹胀,而以进行性加重的呼吸困难为表。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并硬化的慢性丙（CHC）患者接受α干扰素包括派罗欣治疗时存能失代偿和死亡风险。

Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.

结果本例患者临床症状既无明显胸痛,也无腹痛与腹胀,而以进行性加重的呼吸困难为表。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并肝硬化的慢性丙肝（CHC）患者接受α干扰素包括派罗欣治疗时存在肝功能和死亡风险。

Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.

结果本例患者临床症状既无明显胸,也无胀,而以进行性加重的呼吸困难为表。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并肝硬化的慢性丙肝（CHC）患者接受α干扰派罗欣治疗时存在肝功能失代偿和死亡风险。

Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.

结果本例患者临床症状既无明显胸痛,也无腹痛与腹胀,而以进行性加重困难为表。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并肝硬性丙肝（CHC）患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。

Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.

结果者临床症状既无明显胸痛,也无腹痛与腹胀,而以进行性加重的呼吸困难为表。

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并肝硬化的慢性丙肝（CHC）者接受α干扰素包括派罗欣治疗时存在肝功能失代亡风险。